WO2024055983A1 - Composition de protéine de graine de citrouille et son utilisation - Google Patents
Composition de protéine de graine de citrouille et son utilisation Download PDFInfo
- Publication number
- WO2024055983A1 WO2024055983A1 PCT/CN2023/118501 CN2023118501W WO2024055983A1 WO 2024055983 A1 WO2024055983 A1 WO 2024055983A1 CN 2023118501 W CN2023118501 W CN 2023118501W WO 2024055983 A1 WO2024055983 A1 WO 2024055983A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- composition
- subject
- intestinal
- pumpkin seed
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 119
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 118
- 241000408747 Lepomis gibbosus Species 0.000 title claims abstract description 69
- 235000020236 pumpkin seed Nutrition 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 230000000968 intestinal effect Effects 0.000 claims abstract description 30
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 22
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 22
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 22
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 22
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 16
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 16
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 16
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 16
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- 235000013361 beverage Nutrition 0.000 claims abstract description 11
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 20
- 239000006041 probiotic Substances 0.000 claims description 17
- 235000018291 probiotics Nutrition 0.000 claims description 17
- 244000005709 gut microbiome Species 0.000 claims description 15
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 235000015872 dietary supplement Nutrition 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 235000008504 concentrate Nutrition 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000010408 film Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006194 liquid suspension Substances 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 235000015096 spirit Nutrition 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 235000015961 tonic Nutrition 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- 229960000716 tonics Drugs 0.000 claims description 4
- 239000000047 product Substances 0.000 abstract description 8
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 239000003531 protein hydrolysate Substances 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 105
- 230000036541 health Effects 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 13
- 244000052616 bacterial pathogen Species 0.000 description 9
- 230000007413 intestinal health Effects 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- 150000004666 short chain fatty acids Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229920000617 arabinoxylan Polymers 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 229940095100 fulvic acid Drugs 0.000 description 2
- 239000002509 fulvic acid Substances 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004609 intestinal homeostasis Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- -1 vitamins K and B) Natural products 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 101710083587 Antifungal protein Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 241001299819 Hordeum vulgare subsp. spontaneum Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001668545 Pascopyrum Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention belongs to the technical field of health food and dietary supplements, and specifically relates to compositions of pumpkin seed protein or its isolated protein, hydrolyzed protein, concentrated protein and its use in medicines, nutritional supplements, health products, food, beverages and animal feeds. Related applications.
- Intestinal flora plays a very important role in the human body. It is regarded as another "hidden organ” of the human body and carries the human body's "second gene". Therefore, the human body is also described as a super organism. Intestinal flora regulate intestinal homeostasis through interaction with the host; imbalance of intestinal homeostasis caused by various reasons will affect human health and lead to various diseases.
- Lactobacillus acidophilus mainly exists in the small intestine and releases lactic acid, acetic acid and some antibiotics that act on harmful bacteria. It is an intestinal probiotic; Streptococcus thermophilus is an oxygen-consuming Gram-positive bacterium that exists in the human body. A kind of beneficial bacteria in the intestines that can help people with lactose intolerance digest lactose; Bifidobacterium is an important intestinal beneficial microorganism, which has nutritional, anti-tumor and immune-enhancing effects on human health, plays a biological barrier, and improves gastrointestinal function. It has various physiological functions such as intestinal function, anti-aging, etc. Typical representatives include Bifidobacterium longum, Bifidobacterium lactis, etc. Escherichia coli is an opportunistic pathogen and is a gram-negative bacterium. Under certain conditions, it can cause gastrointestinal infection or urinary tract and other local tissue and organ infections in humans and animals.
- Intestinal probiotics can synthesize a variety of vitamins (mainly vitamins K and B), participate in the digestion of food (such as carbohydrates), produce lactic acid, promote intestinal peristalsis, inhibit the growth of pathogenic bacteria and decompose harmful substances, and activate the immune system , maintaining the balance of intestinal flora is indispensable to human health.
- vitamins mainly vitamins K and B
- the regulation of intestinal flora and the improvement of intestinal microenvironment can be achieved through exogenous supplementation of probiotics; probiotics must reach a sufficient quantity to be effective, and have high requirements on preparation technology, storage conditions, price, etc.
- Pathogenic bacteria produce pathogenic substances and cause host infection. In order to maintain intestinal health, it is necessary to promote the proliferation of intestinal probiotics and reduce the number of intestinal pathogenic bacteria.
- pumpkin seeds contain a large amount of fat, protein, phytosterols, various minerals and other nutrients, and their health value has been recognized around the world.
- people have begun to study the extraction, isolation and utilization of pumpkin seed protein from pumpkin seeds.
- Studies have shown that the antifungal protein extracted from naked pumpkin seeds has significant growth inhibitory activity against common agricultural pathogenic bacteria; the activity of extracted from pumpkin seeds The protein has N-glycosidase activity and shows a strong inhibitory effect on the proliferation of human melanoma cells. These studies indicate that pumpkin seed protein has certain physiological activity.
- pumpkin seed protein has high nutritional value and has some applications in other aspects, its development and utilization in health food and medicine are not enough. Protein, as an important nutrient, has received increasing attention for its impact on intestinal health. Intestinal flora can participate in the body's protein metabolism. Food protein will affect the composition and balance of the intestinal flora, and changes in the intestinal flora affect the body's utilization of protein. If pumpkin seed protein with the ability to regulate intestinal health can be extracted, the application scope of pumpkin seed protein can be expanded, and multifunctional peptide resources can be enriched, which is also crucial for improving intestinal health and/or preventing chronic diseases and complications.
- the present invention provides a culture medium that can promote the proliferation of intestinal probiotics (beneficial bacteria), reduce pathogenic bacteria (harmful bacteria), and effectively reduce the number of bacteria containing Lactobacillus acidophilus, Streptococcus thermophilus and Bifidobacterium
- the pH value promotes the production of short-chain fatty acids, thereby inhibiting the growth of spoilage bacteria, promoting gastrointestinal motility and the growth of probiotics, and regulating the composition and application of pumpkin seed protein for intestinal health.
- the pumpkin seed protein of the present invention can be added to various products according to different needs or compatible with other ingredients; the protein component is easy to use and has safe ingredients.
- the pumpkin seed protein can be isolated pumpkin seed protein, concentrated pumpkin seed protein or hydrolyzed pumpkin. Any one or more types of seed proteins.
- the invention provides a method of increasing the level of a first intestinal microbiota in a subject, comprising: administering to the subject a composition containing pumpkin seed protein or its isolate, hydrolyzed protein, or protein concentrate. ;
- the composition effectively increases the level of the first intestinal microbiota in the subject;
- the first intestinal microbiota is selected from one or more of the following: Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum, Bifidobacterium lactis.
- the above method further includes reducing the level of E. coli in the subject.
- the first intestinal microbiota are intestinal probiotics.
- the composition is formulated as a nutritional supplement, food, beverage, animal feed, or pharmaceutical.
- compositions are prepared as solid or liquid formulations.
- compositions are in the form of suppositories, tablets, pills, granules, powders, films, capsules, beverages, aerosols, spirits, tinctures, tonics, liquid suspensions, or syrups.
- the composition is administered to the subject at a dosage of 0.1-500g, preferably 1-400g, 2-300g, 3-200g, 5-100g per day.
- the composition can be administered to the subject at a dose of 0.1-10g/kg, 0.5-5g/kg, 1-3g/kg per day.
- the present invention provides a composition containing pumpkin seed protein or its protein isolate, hydrolyzed protein, or concentrated protein in the manufacture of a nutritional supplement for increasing the level of the first intestinal microbiota in a subject
- the first intestinal microflora is selected from one or more of the following: Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum, and Bifidobacterium lactis.
- the first intestinal microbiota are intestinal probiotics.
- the above uses further include reducing the level of E. coli in the subject.
- the composition is administered to the subject at a dose of 0.1-500g, preferably 1-400g, 2-300g, 3-200g, 5-100g per day; the composition is effective to increase the first intestinal tract in the subject level of the microbiota.
- the composition can be administered to the subject at a dose of 0.1-10g/kg, 0.5-5g/kg, 1-3g/kg per day.
- compositions are prepared as solid or liquid formulations.
- compositions are in the form of suppositories, tablets, pills, granules, powders, films, capsules, beverages, aerosols, spirits, tinctures, tonics, liquid suspensions, or syrups.
- the pumpkin seed protein of the present invention is easily absorbed directly by the intestinal tract, can promote the proliferation of intestinal probiotics, reduce the number of intestinal pathogenic bacteria, effectively reduce the pH value of the culture medium containing Lactobacillus acidophilus, Streptococcus thermophilus and Bifidobacterium, and promote The production of short-chain fatty acids, thereby regulating intestinal health and/or overall health; while discovering new functions and nutritional properties of pumpkin seed protein, increasing the added value of pumpkin seed protein utilization.
- Figure 1A is a graph showing the growth curves of Lactobacillus acidophilus and Streptococcus thermophilus in corresponding media with or without pumpkin seed protein.
- Figure 1B is a graph showing the growth curves of two bifidobacteria in corresponding media with or without pumpkin seed protein.
- Figure 2 is a comparison chart of the log number of colonies of E. coli.
- Figure 3 is a comparison chart of log colony values of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium lactis.
- the term "comprises” or “includes” or variations thereof means where the term is used in its non-limiting sense to include the items following the word but not to exclude items not specifically mentioned. It also includes the more restrictive verbs 'consist essentially of' and 'consist of'.
- the terms “subject” or “individual” are used interchangeably to refer to any subject to whom the methods and compositions of the present disclosure may be applied or administered. It is possible for a subject to suffer from a disease or disorder, but the subject need not be ill to benefit from the methods and compositions of the present disclosure. A subject may need to improve his or her gut and/or overall health, but a subject may also have a generally healthy gut and wish to maintain or further improve his or her gut and/or overall health. Accordingly, any subject can take the disclosed compositions or be the recipient of the disclosed methods. As used herein, the term “subject” refers to animals (eg, birds, reptiles, and mammals).
- subjects may include non-primates (e.g., camels, donkeys, zebras, cows, horses, cats, dogs, rats, and mice) and primates (e.g., monkeys, Chimpanzees, humans) mammals.
- non-primates e.g., camels, donkeys, zebras, cows, horses, cats, dogs, rats, and mice
- primates e.g., monkeys, Chimpanzees, humans
- the subject may be a non-human mammal. In other embodiments, the subject can be a human.
- compositions of the present invention may be administered in a variety of ways to achieve the desired effect, including orally, intragastric and parenterally (meaning intravenous and intraarterial as well as other suitable parenteral routes) and the like.
- protein when describing protein concentration, protein molecular weight distribution, protein solubility and protein amino acid content is defined as native protein structure or denatured protein structure or fragments thereof; shall be interpreted broadly and includes intact proteins, polypeptides , oligopeptides, amino acids and mixtures thereof.
- Hydrolyzed protein protein hydrolyzate
- Protein isolate protein isolate
- Protein concentrate protein concentrate
- the term "effective amount” refers to the amount required to achieve the effect as taught herein. Effective amounts herein include, but are not limited to, amounts necessary to increase intestinal probiotics in a subject; and/or to reduce intestinal pathogenic bacteria in a subject; and/or to improve intestinal health and/or overall The amount necessary for health.
- a suitable single dose size is one that achieves the above effects when administered one or more times over a suitable period of time.
- compositions or agents, materials or combinations of compositions and/or dosage forms thereof which are suitable for contact with human and animal tissues, are compatible with the other ingredients of the composition, and do not exhibit undue toxicity, irritation, allergic reaction or Other problems or complications, commensurate with a reasonable benefit/risk ratio.
- the present application found that administration of pumpkin seed protein significantly increased the levels of the first intestinal microbiota in the subjects while reducing the levels of E. coli in the subjects.
- the present invention and embodiments relate to methods and compositions using "pumpkin seed protein-containing" compositions and/or "pumpkin seed protein enhanced” compositions, wherein the pumpkin seed protein-containing compositions comprise pumpkin seed protein-containing compositions Or any combination of protein isolate, protein hydrolyzate, or protein concentrate.
- the methods of the present invention comprise the daily administration of at least 0.1 g, typically 0.1-500 g, 1-400 g, preferably 2-300 g, 3-200 g, 5-100 g, of a pumpkin seed protein-containing composition, depending on the specific formulation and form .
- the amount to be administered can also be 0.1-10g/kg, 0.5-5g/kg, 1-3g/kg of subject's body weight per day, depending on factors such as subject's sensitivity, age, gender and weight, idiosyncratic reactions, etc. Variety.
- One or more doses may be administered one or more times daily or at a suitable frequency for any period of time. For example, an effective dose may be administered daily for one day, several days, multiple days, or indefinitely.
- the pumpkin seed protein-containing composition of the present invention may be formulated as a nutritional or dietary supplement, a (medical) food, an animal feed or a pharmaceutical composition, in liquid or solid form, and may optionally also include nutritional or a pharmaceutically acceptable carrier.
- the compositions when in solid form, the compositions may be formulated as snack bars, yogurt, lozenges, tablets or capsules.
- the compositions when in liquid form, the compositions may be formulated as tinctures, soft gel capsules, liquid capsules, syrups, carbonated beverages, brewed beverages (eg, coffee or tea), juices, energy drinks, sports drinks, or flavored waters.
- pumpkin seed protein-containing compositions and formulations may also be used for veterinary purposes (e.g., animal feed for domestic companion animals ("pets") or animal feed for farm animals.
- the pumpkin seed protein-containing composition may also be provided in the form of a bulk product (for example, in an amount equal to or greater than 100 g, equal to or greater than 1000 g, or equal to or greater than 10 kg) for the production of nutritional supplements, (medical) Food, animal feed or pharmaceuticals.
- contemplated methods of administering a pumpkin seed protein-containing composition include administering at least one probiotic microorganism simultaneously with or subsequent to administration of a pumpkin seed protein-containing composition.
- the composition can also be combined with arabinoxylan (AX), arabinoxylan oligosaccharide (AXOS), xylo-oligosaccharide (XOS), fructooligosaccharide (FOS), galacto-oligosaccharide (GOS), inulin and/or one or a combination of two prebiotics in pectin.
- the pumpkin seed protein-containing compositions of the present invention may be combined with health additives to increase the breadth of health benefits.
- Health additives may be added to the pumpkin seed protein-containing composition in any combination depending on the form of the composition and considerations of desired health effects and product cost.
- Exemplary additives that may be combined with pumpkin seed protein-containing compositions include superoxide dismutase (SOD), compositions containing activators of SOD, foods containing bioavailable SOD, or extracts thereof (e.g., sprouted wheat, Wheatgrass, encapsulated (lipid and/or protein encapsulated) cantaloupe, rye, barley, barley grass, broccoli sprouts, kale, Brussels sprouts and curcuminoids (e.g.
- turmeric copper iodide (CuI ), selenium (Se), fulvic acid, foods containing fulvic acid or their extracts (e.g. potatoes, radish, beets, carrots, root vegetables, blackstrap molasses and shilajit), coenzyme Q10 (ubiquinone) or pyrrolo Quinoline quinone (PQQ).
- CuI copper iodide
- Se selenium
- fulvic acid foods containing fulvic acid or their extracts
- foods containing fulvic acid or their extracts e.g. potatoes, radish, beets, carrots, root vegetables, blackstrap molasses and shilajit
- coenzyme Q10 ubiquinone
- PQQQ pyrrolo Quinoline quinone
- each activated strain into each culture medium with or without the addition of pumpkin seed protein or its isolated protein, hydrolyzed protein, or concentrated protein at an inoculum volume of 2%: Lactobacillus acidophilus (L. acid) 563 in MRS liquid
- the culture medium was statically cultured at 37°C; Streptococcus thermophilus (S.thermophilus) 176 was cultured statically in Eliker medium at 42°C; Bifidobacterium longum (Bifido.longum) BB536 and Bifidobacterium lactis ( Bifido.
- lactis BB12 were cultured anaerobically at 37°C in mMRS medium (MRS medium containing 0.05% L-cysteine hydrochloride). The cultures were cultured to a certain point in the logarithmic phase, and then the pH values of the two fermentation broths in each group were measured, and viable bacteria were counted. The results are shown in Table 1.
- pumpkin seed protein promotes the production of short-chain fatty acids, thereby inhibiting the growth of spoilage bacteria, promoting gastrointestinal motility and the growth of probiotics; the number of viable bacteria in the protein group increased, indicating that pumpkin seed protein can effectively increase the growth rate of Lactobacillus acidophilus, Viable bacterial counts of Streptococcus thermophilus, Bifidobacterium longum, and Bifidobacterium lactis.
- Figure 1A is a growth curve diagram of Lactobacillus acidophilus 563 and Streptococcus thermophilus 176 in corresponding media with or without the addition of pumpkin seed protein or its isolated protein, hydrolyzed protein, or concentrated protein.
- Figure 1B is a graph showing the growth curves of Bifidobacterium longum BB536 and Bifidobacterium lactis BB12 in corresponding media with or without the addition of pumpkin seed protein or its isolated protein, hydrolyzed protein, or concentrated protein.
- Figure 1A when pumpkin seed protein was added for culture, the OD values of Lactobacillus acidophilus 563 and Streptococcus thermophilus 176 changed compared to when pumpkin seed protein was not added.
- the blank control group was fed normal feed and an equal volume of distilled water
- the pumpkin seed protein group was fed pumpkin seed protein in addition to normal feed.
- the pumpkin seed protein group was given about 1-3g/kg of pumpkin seed protein or its isolated protein, hydrolyzed protein, or concentrated protein every day.
- mice After 30 days of feeding, the feces of the two groups of mice were collected for intestinal flora culture and analysis. Manually collect fresh fecal balls from the end of the rat rectum, dilute them to 10 -9 , spot them on various culture media, and culture them under appropriate conditions. After culturing, high-throughput sequencing and metabolomic analysis of 16S rDNA of intestinal flora were performed. The number of bacteria was counted in colony forming units lg (CFU/g), and the changes in bacterial colonies were comparatively analyzed. The results are shown in Figures 2 and 3.
- Figure 2 is a comparison chart of the log number of colonies of E. coli in the blank group and the pumpkin seed protein treatment group. As shown in Figure 2, compared with the blank group, the E. coli in the pumpkin seed protein group decreased by 12.07%, indicating that pumpkin seed protein can effectively reduce the content of E. coli.
- Figure 3 is a comparison chart of the logarithmic colony values of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium lactis in the blank group and the pumpkin seed protein treatment group.
- Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium lactis increased by 4.97%, 11.66%, 5.65% and 5.58% respectively in the pumpkin seed protein group. , indicating that pumpkin seed protein can effectively promote the in vivo proliferation of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium lactis.
- the content of other intestinal probiotics can also be increased, such as Lactobacillus rhamnosus, Bifidobacterium adolescentis, Lactobacillus bulgaricus, etc.; the content of other intestinal pathogenic bacteria can be reduced, Such as Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella, etc. This allows the levels of gut microbiota to be maintained and/or restored to near-normal levels, which is highly beneficial for maintaining gut health and/or overall health.
- the pumpkin seed protein of the present invention can promote the proliferation of intestinal probiotics, reduce the number of pathogenic bacteria, effectively reduce the pH value of the culture medium containing Lactobacillus acidophilus, Streptococcus thermophilus and Bifidobacterium, promote the production of short-chain fatty acids, and thereby regulate the intestinal tract.
- Tao Health can be combined with different ingredients according to different needs. It can not only meet the needs of vegetarians but also regulate intestinal health and/or overall health; it provides a basis for the future development and utilization of pharmaceuticals and health products containing pumpkin seed protein and corresponding peptides. and laid the foundation for the production and application of various products.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Une composition d'une protéine de graine de citrouille ou d'une protéine isolée, un hydrolysat de protéine ou une protéine concentrée de celle-ci, et son utilisation dans la préparation d'un médicament, d'un produit nutritionnel, d'un produit de soins de santé, d'un produit alimentaire, d'une boisson et d'une alimentation animale pour réguler la flore intestinale. La flore intestinale est choisie parmi un ou plusieurs des éléments suivants : Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum et Bifidobacterium lactis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211114142.1A CN117731007A (zh) | 2022-09-14 | 2022-09-14 | 南瓜籽蛋白组合物和其应用 |
CN202211114142.1 | 2022-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024055983A1 true WO2024055983A1 (fr) | 2024-03-21 |
Family
ID=90274289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/118501 WO2024055983A1 (fr) | 2022-09-14 | 2023-09-13 | Composition de protéine de graine de citrouille et son utilisation |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117731007A (fr) |
WO (1) | WO2024055983A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105520151A (zh) * | 2016-01-26 | 2016-04-27 | 青岛森淼实业有限公司 | 果蔬蛋白粉营养补充剂及其制备方法 |
CN106820156A (zh) * | 2017-02-17 | 2017-06-13 | 福建康是美生物科技有限公司 | 一种调节肠道菌群健康的益生菌组合物 |
CN108310238A (zh) * | 2018-03-15 | 2018-07-24 | 武汉虹辰远荣生物制品有限公司 | 一种防治腹泻的益生菌组合物 |
CN109662311A (zh) * | 2018-12-13 | 2019-04-23 | 武汉森澜生物科技有限公司 | 具有润肠通便功能的酵素及其制备方法和应用 |
CN111019990A (zh) * | 2018-10-09 | 2020-04-17 | 杏辉天力(杭州)药业有限公司 | 一种南瓜籽肽粉及其制备方法和用途 |
-
2022
- 2022-09-14 CN CN202211114142.1A patent/CN117731007A/zh active Pending
-
2023
- 2023-09-13 WO PCT/CN2023/118501 patent/WO2024055983A1/fr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105520151A (zh) * | 2016-01-26 | 2016-04-27 | 青岛森淼实业有限公司 | 果蔬蛋白粉营养补充剂及其制备方法 |
CN106820156A (zh) * | 2017-02-17 | 2017-06-13 | 福建康是美生物科技有限公司 | 一种调节肠道菌群健康的益生菌组合物 |
CN108310238A (zh) * | 2018-03-15 | 2018-07-24 | 武汉虹辰远荣生物制品有限公司 | 一种防治腹泻的益生菌组合物 |
CN111019990A (zh) * | 2018-10-09 | 2020-04-17 | 杏辉天力(杭州)药业有限公司 | 一种南瓜籽肽粉及其制备方法和用途 |
CN109662311A (zh) * | 2018-12-13 | 2019-04-23 | 武汉森澜生物科技有限公司 | 具有润肠通便功能的酵素及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN117731007A (zh) | 2024-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1945235B1 (fr) | Des probiotiques pour influencer le métabolisme des graisses et l'obésité | |
CN101486986B (zh) | 一种嗜酸乳杆菌冻干菌粉的制备方法 | |
JP5903380B2 (ja) | 経口用皮膚性状改善剤 | |
US20080102061A1 (en) | Use hydrolyzed medium containing microorganisms medicinally | |
US20120020942A1 (en) | Novel Lactobacillus Strains And Their Use Against Helicobacter Pylori | |
WO2019112054A1 (fr) | Nouvelle bactérie bifidobacterium, et composition contenant cette bactérie | |
WO2011034166A1 (fr) | Agent anti-obésité, aliment ou boisson anti-obésité, agent d'amélioration de tolérance au glucose et aliment ou boisson pour l'amélioration de la tolérance au glucose | |
TW200944215A (en) | Lactobacillus isolates having anti-inflammatory activities and uses of the same | |
CN102245191A (zh) | 用于改善口腔健康的组合物和方法 | |
EP3725321A1 (fr) | Composition contenant une bactérie appartenant au genre bifidobacterium en tant que substance active | |
KR20140140387A (ko) | 나노형 김치 유산균 | |
JP7296454B2 (ja) | 炎症関連胃腸障害の処置のためのプロバイオティクスの組み合わせ | |
JP2016520305A (ja) | 消化管微生物叢中のラクノスピラ科細菌及び体重との関連性 | |
CN111011856A (zh) | 用于缓解胃病的组合物、其制备方法及用于缓解胃病的食品 | |
TW201542216A (zh) | 新穎副乾酪乳桿菌(Lactobacillus paracasei)株 | |
JP5592640B2 (ja) | 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤、その製造方法、視床下部−下垂体−副腎皮質系の活動抑制剤、及び交感神経−副腎髄質系の活動抑制剤 | |
CN111212575A (zh) | 肌肉增量用组合物 | |
CN110692885A (zh) | 一种用于缓解便秘的益生菌保健饮料 | |
KR101545551B1 (ko) | 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물 | |
WO2019112053A1 (fr) | Nouvelle bactérie bifidobacterium, et composition contenant cette bactérie | |
WO2024027401A1 (fr) | Procédé et composition pour améliorer le microbiote intestinal | |
AU2004208084A1 (en) | New strains of Bifidobacterium having the ability to produce glutamine | |
CN111685255B (zh) | 一种增强免疫功能的益生菌固体饮料及其制备方法 | |
WO2024055983A1 (fr) | Composition de protéine de graine de citrouille et son utilisation | |
KR101779719B1 (ko) | 신규한 락토바실러스 케피아노파시엔스 dn1 균주 및 이를 포함하는 변비의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23864715 Country of ref document: EP Kind code of ref document: A1 |